Prognostic status of p53 protein accumulation in canine malignant mammary tumours

• Autorzy: Lopuszynski W , Szczubial M. , Komsta R.
• Języki publikacji: EN

Abstrakty

EN

The expression of p53 protein was determined by the immunohistochemical study with CM-1 polyclonal antibody. The investigations were performed on formalin-fixed and paraffin-embedded tissue samples of mammary tumours obtained from 131 bitches during surgery. The p53 protein accumulation was detected in 37 tumours (28.24%). No correlation was found between p53 protein overexpression and histological type, tumour size, or regional lymph node status. However, its relationship with a histologic malignant grade approached statistical significance (P=0.067). After the 24-month follow-up period, survival analysis revealed a shortened disease-free survival and overall survival time of the dogs with tumours, which overexpressed p53 protein. Only in the case of survival time, the difference was close to the borderline of statistical significance (P=0.061). The research data presented herein, being not fully explicit, have indicated a correlation of p53 protein accumulation with worse prognosis in canine mammary tumours, although the results do not allow recognising p53 protein accumulation as a suitable prognostic factor.

Słowa kluczowe

EN

dog; mammary tumour; p53 protein; accumulation; malignant mammary tumour; canine mammary tumour; immunohistochemistry; prognosis

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2010
• Tom: 54
• Numer: 1
• Opis fizyczny: p.105-111,fig.,ref.

Twórcy

autor

Lopuszynski W

• Life Sciences University, 20-612 Lublin, Poland

autor

Szczubial M.

autor

Komsta R.

Bibliografia

• 1. Chu L.L., Rutteman G.R., Kong J.M.C., Ghahremani M., Schmeing M., Misdorp W., van Garderen E., Pelletier J.: Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res Treat 1998, 50, 11-15.
• 2. Eastman A.: Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 2004, 91, 223-231.
• 3. Feki A., Irminger-Finger I.: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004, 52, 103-116.
• 4. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., Ruby S.G., O'Malley F., Simpson J.F., Connolly J.L., Hayes D.F., Edge S.B., Lichter A., Schnitt S.J.: Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000, 124, 966- 978.
• 5. Gamblin R.M., Sagartz J.E., Couto C.G.: Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. Am J Vet Res 1997, 58, 857-863.
• 6. Guevara-Fujita M.L., Loechel R., Venta P.J., Yuzbasiyan-Gurkan V., Brewer G.J.: Chromosomal assignment of seven genes on canine chromosomes by fluorescence in situ hybridization. Mamm Genome 1996, 7, 268-270.
• 7. Haga S., Nakayama M., Tatsumi K., Maeda M., Imai S., Umesako S., Yamamoto H., Hilgers J., Sarkar N.H.: Overexpression of p53 gene product in canine mammary tumors. Oncol Rep 2001, 8, 1215-1219.
• 8. Hall P.A., Ray A., Lemoine N.R., Midgley C.A., Krausz T., Lane D.P.: p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991, 338, 513.
• 9. Inoue M., Shiramizu K.: Immunohistochemical detection of p53 and c-myc proteins in canine mammary tumors. J Comp Pathol 1999, 120, 169-175.
• 10. Kaplan E.L., Meier P.: Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958, 53, 457- 481.
• 11. Lacroix M., Toillon R. A., Leclercq G.: p53 and breast cancer, an update. Endocr Relat Cancer 2006, 13, 293- 325.
• 12. Lai H., Ma F., Trapido E., Meng L., Lai S.: Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. Breast Cancer Res 2004, 83, 57-66.
• 13. Lee Ch., Kim W., Lim J., Kang M., Kim D., Kweon O.: Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 2004, 5, 63- 69.
• 14. Lee Ch., Kweon O.: Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors. J Vet Sci 2002, 3, 321-325.
• 15. Misdorp W.: Tumors of the mammary gland. In: Tumors in Domestic Animals. Edited by Meuten D.J. Iowa State Press, Ames 2002, pp. 575-606.
• 16. Misdorp W., Else R.W., Hellmen E., Lipscomb T.P.: Histological Classification of Mammary Tumors of the Dog and the Cat. WHO Histological Classification of Tumors of Domestic Animals, Vol. VII. Armed Forces Institute of Pathology, Washington, D.C., 1999.
• 17. Muto T., Wakui S., Takashashi H., Maekawa S., Masaoka T., Ushigome S., Furusato M.: p53 gene mutation occurring in spontaneous benign and malignant mammary tumours of the dog. Vet Pathol 2000, 37, 248- 253.
• 18. Norberg T., Lennerstrand J., Inganas M., Bergh J.: Comparison between protein measurments using luminometric immunoassay and immunohistochemistry with detection of p53 gene mutation using eDNA sequencing in human breast tumors. Int J Cancer 1998, 79, 376-383.
• 19. Owen L.N.: TNM classification of tumours in domestic animals. Bull World Health Organisation, Geneva, 1980.
• 20. Petitjean A., Achatz M.I., Boresen-Dale A.L., Haiuaut P., Olivier M.: TP53 mutations in humans cancer: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26, 2157-2165.
• 21. Pietilainen T., Lipponen P., Aaltomaa S., Eskelinen M., Kosma V.M., Syrjänen K.: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 1995, 177, 225-232.
• 22. Reed W., Hannisdal E., Boehler P.J., Gundersen S., Host H., Marthin J.:The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 2000, 88, 804-813.
• 23. Rodo A., Malicka E. Immunohistochemical expression of protein p53 in neoplasms of the mammary gland in bitches. Polish J Vet Sci 2008, 11, 89-95.
• 24. Rungsipipat A., Tateyama S., Yamaguchi R., Uchida K., Miyoshi N., Hayashi T.: Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p-53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci 1999, 61, 27-32.
• 25. Schafer K.A., Kelly G., Schräder R., Griffith W.C., Mauggenburg B.A., Tierney L.A., Lechner J.F., Janovitz E.B., Hahn F.F.: A canine model of familial mammary gland neoplasia. Vet Pathol 1998, 35, 168-177.
• 26. Veldhoen N., Milner J.: Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein. Oncogene 1998, 16, 1077-1084.
• 27. Vogelstein B., Kinzler K.W.: Cancer genes and the pathways they control. Nat Med 2004, 10, 789-799.
• 28. Wakui S., Muto T., Yokoo K., Yokoo R., Takashashi H., Masaoka T., Hano H., Furusato M.: Prognostic status of p53 gene mutation in canine mammary carcinoma. Anticancer Res 2001, 21, 611-616.
• 29. Walker D.R., Bond J.P., Tarone R.E., Harris C.C., Makalowski W., Boguski M.S., Greenblatt M.S.: Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural an function features. Oncogene 1999, 18, 211-218.
• 30. Wayne R.K., Ostrander E.A.: Origin, genetic diversity, and genome structure of the domestic dog. Bioessays 1999, 21, 247-257.
• 31. Zacchetti A., Van Garderen E., Rutteman G.R.: Immunohistochemical evaluation of p53 expression with different antibodies in malignant canine tumours with or without p53 gene mutation. Vet Comp Oncol 2007, 5, 108-118.